Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients

Immunology

Volumn 110, Issue 1, 2003, Pages 131-140

  Contin, Cécile ^a   Pitard, Vincent ^a   Delmas, Yahsou ^b   Pelletier, Nadège ^c   Defrance, Thierry ^c   Moreau, Jean François ^a   Merville, Pierre ^a,b   Déchanet Merville, Julie ^a  

^a CNRS Bordeaux Segalen University   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CREATININE; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UREMIA; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD40; BINDING, COMPETITIVE; CD40 LIGAND; CELLS, CULTURED; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNE TOLERANCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SOLUBILITY; UREMIA;

EID: 0042318701     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01716.x     Document Type: Article

References (48)

1. Higgins RM. Infections in a renal unit. Q J Med 1989; 70:41-51.
2. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved - editorial. Am J Nephrol 1998; 18:89-95.
3. Crosnier J, Jungers P, Courouce AM et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1981; 1:797-800.
4. Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25:124-8.
5. Benhamou E, Courouce AM, Jungers P, Laplanche A, Degos F, Brangier J, Crosnier J. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21:143-7.
6. Jungers P, Chauveau P, Courouce AM, Devillier P, Excler JL, Bailleux F, Saliou P. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. J Infect Dis 1994; 169:399-402.
7. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996; 16:183-91.
8. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fc gamma receptors in end-stage renal disease [see comments]. N Engl J Med 1990; 322:717-22.
9. Girndt M, Sester U, Kaul H, Kohler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998; 9:1689-96.
10. Girndt M, Sester M, Sester U, Kaul H, Kohler H. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001; 59:1382-9.
11. Girndt M, Sester U, Sester M, Deman E, Ulrich C, Kaul H, Kohler H. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60:2385-91.
12. Degiannis D, Mowat AM, Galloway E, Tsakiris D, Briggs JD, Junor BJ, Parrott DM. In vitro analysis of B lymphocyte function in uraemia. Clin Exp Immunol 1987; 70:463-70.
13. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12:881-922.
14. Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus- dependent B-cell activation. Immunol Today 1992; 13:431-3.
15. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15:406-11.
16. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
17. Hollenbaugh D, Grosmaire LS, Kullas CD et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992; 11:4313-21.
18. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994; 367:425-8.
19. Rousset F, Garcia E, Banchereau J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med 1991; 173:705-10.
20. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996; 17:487-92.
21. + T-cell responses. Immunol Today 1996; 17:410-4.
22. Blair PJ, Riley JL, Harlan DM et al. CD40 ligand (CD154) triggers a short-term CD4 (+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000; 191:651-60.
23. + T lymphocytes. J Immunol 1994; 152:1523-31.
24. Aruffo A, Farrington M, Hollenbaugh D et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72:291-300.
25. Allen RC, Armitage RJ, Conley ME et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome [see comments]. Science 1993; 259:990-3.
26. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM [see comments]. Nature 1993; 361:541-3.
27. Kroczek RA, Graf D, Brugnoni D et al. Defective expression of CD40 ligand on T cells causes 'X-linked immunodeficiency with hyper-IgM (HIGM1)'. Immunol Rev 1994; 138:39-59.
28. van Kooten C, Galliard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, Blanchard D. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol 1994; 24:787-92.
29. Valle A, Zuber CE, Defrance T, Djossou O, De Rie M, Banchereau J. Activation of human B lymphocytes through CD40 and interleukin 4. Eur J Immunol 1989; 19:1463-7.
30. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000; 235:71-80.
31. Dechanet J, Grosset C, Taupin JL, Merville P, Banchereau J, Ripoche J, Moreau JF. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997; 159:5640-7.
32. Defrance T, Vanbervliet B, Aubry JP et al. B cell growth-promoting activity of recombinant human interleukin 4. J Immunol 1987; 139:1135-41.
33. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995; 182:1265-73.
34. Fluckiger AC, Garrone P, Durand I, Galizzi JP, Banchereau J. Interleukin 10 (1L-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med 1993; 178:1473-81.
35. Defrance T, Vanbervliet B, Aubry JP, Banchereau J. Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2. J Exp Med 1988; 168:1321-37.
36. Arpin C, Dechanet J, Van Kooten C et al. Generation of memory B cells and plasma cells in vitro. Science 1995; 268:720-2.
37. Holler N, Kataoka T, Bodmer JL et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237:159-73.
38. Marshall LS, Aruffo A, Ledbetter JA, Noelle RJ. The molecular basis for T cell help in humoral immunity. CD40 and its ligand, gp39. J Clin Immunol 1993; 13:165-74.
39. + T cells. J Immunol 1993; 151:2497-510.
40. Yellin MJ, Sippel K, Inghirami G et al. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol 1994; 152:598-608.
41. Schwabe RF, Engelmann H, Hess S, Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol 1999; 117:153-8.
42. Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A 2001; 98:1751-6.
43. Dri P, Gasparini C, Menegazzi R et al. TNF-Induced shedding of TNF receptors in human polymorphonuclear leukocytes: role of the 55-kDa TNF receptor and involvement of a membrane-bound and non-matrix metalloproteinase. J Immunol 2000; 165:2165-72.
44. Hansen HP, Dietrich S, Kisseleva T et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha- converting enzyme. J Immunol 2000; 165:6703-9.
45. Sharma MD, Leite de Moraes M, Zavala F, Pontoux C, Papiernik M. Induction and inhibition of CD40-CD40 ligand interactions: a new strategy underlying host-virus relationships. J Immunol 1998; 161:5357-65.
46. Gray D, Dullforce P, Jainandunsing S. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J Exp Med 1994; 180:141-55.
47. Perez-Melgosa M, Hollenbaugh D, Wilson CB. Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. J Immunol 1999; 163:1123-7.
48. Arakawa M. Long-term multicentre study on beta 2-microglobulin removal by PMMA. Nephrol Dial Transplant 1991; 6 (Suppl. 2):69-74.